

trioid histologies as different entities (n=271 endometrioid (EEC) type, n=62 non-EEC type including n=10 mixed carcinomas, and


 -2 - EEC Mixed SEC
 -2 - EEC Mixed SEC
 -1 - EEC Mixed SEC
 -2 - EEC Mixed SEC

 Figure Supplementary 1. Boxplots of the described validated biomarkers for histological type representing different non-endome 

2 3 4

1

n=52 serous (SEC) carcinomas).



**Figure Supplementary 2**. Biomarkers related to FIGO stage with its respective boxplots, and molecular classification of the validated biomarkers. (a) Table of the proteins that were found differentially expressed between (a) Any of the FIGO stages in any of the tested cohorts. Highlighted in yellow, the specific cohort in which that protein was found to be differentially expressed between FIGO stages. Proteins highlighted in blue are those validated in more than one cohort, and therefore, the ones that we considered as validated biomarkers; (b–d) Boxplots showing the expression of the significant biomarkers for FIGO stage in each cohort of patients: TCGA RNA-Seq data, CPTAC RNA-Seq data, and CPTAC proteomic data, respectively; (e–g) Boxplots showing the expression of the significant biomarkers for molecular classification in each cohort of patients: TCGA RNA-Seq data, CPTAC RNA-Seq data, and CPTAC proteomic data, respectively; (e–g) Boxplots showing the expression of the significant biomarkers for molecular classification in each cohort of patients: TCGA RNA-Seq data, CPTAC RNA-Seq data, and CPTAC proteomic data, respectively; (e–g) Boxplots showing the expression of the significant biomarkers for molecular classification in each cohort of patients: TCGA RNA-Seq data, CPTAC RNA-Seq data, and CPTAC proteomic data, respectively. *Literature: literature revision from Coll-de la Rubia E et al.*, 2020 [1]; *T\_RNAseq: RNA-Seq data of the CPTAC's cohort; C\_prot: proteomic data of the CPTAC's cohort.* 

2 of 5

	Function [CC]	EMT		ostic summary
Gene Name	- Uniprot Function	- EMTome EMT-related proteins	- The Humar	Protein Atlas Unfavorable
ASRGL1	Has both L-asparaginase and beta-aspartyl peptidase activity.	No	colorectal, renal	liver
ATAD2	Involved in the estrogen-induced cell proliferation and cell cycle progression of breast cancer cells.	No		lung, renal
BUB1	Serine/threonine-protein kinase that performs 2 crucial functions during mitosis: it is essential for spindle- assembly checkpoint signaling and for correct chromosome alignment.	No		liver, pancreatic
CAPG	Calcium-sensitive protein which reversibly blocks the barbed ends of actin filaments but does not sever preformed actin filaments.	Yes	renal	liver
CCNE1	Essential for the control of the cell cycle at the G1/S (start) transition.	No		liver, <b>ovarian</b>
CDC20	Required for full ubiquitin ligase activity of the anaphase promoting complex/cyclosome (APC/C).	No		liver, pancreatic, renal
CDKN1A	Binds to and inhibits cyclin-dependent kinase activity, preventing phosphorylation of critical cyclin-dependent kinase substrates and blocking cell cycle progression.	Yes	renal	lung
CDKN2A	Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6.	Yes	head and neck	liver, renal
ERBB2	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. In the nucleus is involved in transcriptional regulation. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.	Yes	renal	pancreatic
ESR1	Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Also mediates membrane-initiated estrogen signaling involving various kinase cascades.	Yes		
FASN	Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH.	No		<b>cervical</b> , renal
HDGF	[Isoform 1]: Acts as a transcriptional repressor. Has mitogenic activity for fibroblasts. Heparin-binding protein.	Yes	ovarian	liver
HMGA1	HMC-I/Y bind preferentially to the minor groove of A+T rich regions in double-stranded DNA. They are also involved in the transcription regulation of genes containing, or in close proximity to A+T-rich regions.	Yes		liver, lung, pancreatic
L1CAM	Neural cell adhesion molecule involved in the dynamics of cell adhesion and in the generation of transmembrane signals at tyrosine kinase receptors.	Yes		head and neck, lung, renal
MACC1	Acts as a transcription activator for MET and as a key regulator of HGF-MET signaling. Promotes cell motility, proliferation and hepatocyte growth factor (HGF)-dependent.	Yes	renal	
MCM6	Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells.	No		liver, melanoma, renal
MCM7	Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Required for S-phase checkpoint activation upon UV-induced damage.	Yes	cervical	liver
MSH2	Component of the post-replicative DNA mismatch repair system (MMR).	No		liver, pancreatic
MSH6	Component of the post-replicative DNA mismatch repair system (MMR).	No		liver, renal
PAX8	Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells.	No		
PGR	The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues.	Yes		
PIGR	Mediates selective transcytosis of polymeric IgA and IgM across mucosal epithelial cells. Binds polymeric IgA and IgM at the basolateral surface of epithelial cells.	No	<b>breast</b> , renal	
PTK2	Non-receptor protein-tyrosine kinase that plays an essential role in regulating cell migration, adhesion, spreading, reorganization of the actin cytoskeleton, formation and disassembly of focal adhesions and cell protrusions, cell cycle progression, cell proliferation and apoptosis.	Yes		breast
S100A1	Small calcium binding protein that plays important roles in several biological processes such as Ca(2+) homeostasis, chondrocyte biology and cardiomyocyte regulation.	No		renal
SCGB2A1	May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones.	No	colorectal, renal	
TMEFF2	May be a survival factor for hippocampal and mesencephalic neurons. The shedded form up-regulates cancer cell proliferation, probably by promoting ERK1/2 phosphorylation.	No	Gene product i	s not prognostic
TPX2	Spindle assembly factor required for normal assembly of mitotic spindles.	No		liver, lung, pancreatic, renal
TRA2B	Sequence-specific RNA-binding protein which participates in the control of pre-mRNA splicing. Can either activate or suppress exon inclusion.	No	ovarian	liver
UCHL1	Ubiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins (Probable). This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes (By similarity).	Yes		urothelial
VIM	Vimentins are class-III intermediate filaments found in various non-epithelial cells, especially mesenchymal cells. Vimentin is attached to the nucleus, endoplasmic reticulum, and mitochondria, either laterally or terminally.	Yes		renal

16

Figure Supplementary 3. Description of the functions of the proteins described as validated biomarkers in our study, their relation 17 to the epithelial-mesenchymal transition, and their prognostic behavior in other types of cancer. Highlighted in bold are gynecolog-18 ical cancers in which a prognostic association of that specific protein has been described. Source: Uniprot [2], EMTome [3], and The Human Protein Atlas (www.proteinatlas.org).

19 20

		Small molecule			Antibody	
Target symbol	Clinical precedence	Discovery precedence	Predicted tractable	Clinical precedence	Predicted tractable high	Predicted tractable mid-
	precedence	precedence	tractable	precedence	confidence	low confidence
ASRGL1						
ATAD2 Aurkb						
SUB1						
CCNA2						
CCNB1						
CCNE1						
CDC20						
CDKN1A						
ERBB2						
ESR1 FASN						
HDGF						
L1CAM		I				
MSH2						
MSH6						
PGR						
PIGR						
PLK1						
PTK2 S100A1						
SCGB2A1						
TMEFF2						
ГРХ2						
UCHL1						
VIM	AT-9283 (multiple r	nveloma): TOZASER	TIB (leukemia): DAI	JUSERTIB (multiple	e myeloma): ENMD-	2076 (soft tissue
VIM AURKB	sarcoma); BI-811283 ILORASERTIB (can CENISERTIB (lymp (neoplasm); MK-659	nyeloma); TOZASER (acute myeloid leuke œr); TAK-901 (acute r hoid neoplasm); AM( 92 (neoplasm); PF-038	emia); BARASERTIB nyeloid leukemia); S G-900 (cancer); CYC- 14735 (neoplasm)	(acute myeloid leul iNS-314 (neoplasm); 116 (neoplasm); TTI	kemia); CHIAURAN KW-2449 (acute mye P-607 (lymphoma); G	IB (ovarian cancer); eloid leukemia); SK-1070916
	sarcoma); BI-811283 ILORASERTIB (can CENISERTIB (lymp (neoplasm); MK-655 AFATINIB (non-sm (neoplasm); DACO0 (breast cancer); TES VARLITINIB (cholal (metastasis); CANEI	(acute myeloid leuke cer); TAK-901 (acute r hoid neoplasm); AM( 22 (neoplasm); PF-038 all cell lung carcinom MITINIB (non-small o EVATINIB (non-small ngiocarcinoma); BMS RTINIB (breast neopla 8 (glioblastoma multif	emia); BARASERTIB nyeloid leukemia); 5 2-900 (cancer); CYC- 14735 (neoplasm) a); NERATINIB (nec ell lung carcinoma); 1 cell lung carcinoma 690514 (non-small c asm); HEMAY-022 (t	(acute myeloid leui INS-314 (neoplasm); I16 (neoplasm); TTI plasm); VANDETA TUCATINIB (HER2 ); POZIOTINIB (nor Ill lung carcinoma); reast cancer); CUD	xemia); CHIAURAN KW-2449 (acute mye -607 (lymphoma); G NIB (thyroid cancer); Positive Breast Carci -small cell lung carc SAPITINIB (breast ca C-101 (head and neck	IB (ovarian cancer); eloid leukemia); SK-1070916 LAPATINIB noma); PYROTINIB inoma); uncer); CP-724714 < malignant
AURKB ERBB2 (Small	sarcoma); BI-S11283 ILORASERTIB (cann CENISERTIB (theoplasm); MK-655 AFATINIB (non-sm (neoplasm); DACOO (breast cancer); TES VARLITINIB (cholai (metastasis); CANEI neoplasia); AEE-788 412 (neoplasm); JNJ TRASTUZUMAB E TRASTUZUMAB C	(acute myeloid leuke cer); TAK-901 (acute r hoid neoplasm); AM( 22 (neoplasm); PF-038 all cell lung carcinom MITINIB (non-small o EVATINIB (non-small ngiocarcinoma); BMS RTINIB (breast neopla 8 (glioblastoma multif	emia); BARASERTIB myeloid leukemia); Y 2-900 (cancer); CYC- 2-900 (cancer); CYC- 14735 (neoplasm) a); NERATINIB (nec ell lung carcinoma; 6-00514 (non-small ca asm); HEMAY-022 (t forme); MUBRITINIB m); TRASTUZUMAIN t cancer); MARGETI	(acute myeloid leui NS-314 (neoplasm); 116 (neoplasm); TIT plasm); VANDETA TUCATINIB (HER2 ); POZIOTINIB (nor 11 lung carcinoma); (breast neoplasm); 8 (breast carcinoma)	xemia); CHIAURAN; KW-2449 (acute myy 2-607 (lymphoma); G NIB (thyroid cancer); Positive Breast Carci n-small cell lung carc SAPITINIB (breast ca C-101 (head and neek AC-480 (cancer); TAI ; ; PERTUZUMAB (r	IB (ovarian cancer); eloid leukemia); SK-1070916 LAPATINIB noma); PYROTINIB inoma); pyROTINIB inoma); cP-724714 ; calignant (-285 (cancer); MP- ueoplasm);
AURKB ERBB2 (Small molecules) ERBB2	sarcoma); BI-S11283 ILORASERTIB (cann CENISERTIB (inpup (neoplasm); MK-655 AFATINIB (non-sm (neoplasm); DACOI (breast cancer); TES VARLITINIB (cholai (metastasis); CANEI (metastasis); CANEI (metastasis); CANEI 12 (neoplasm); JNJ TRASTUZUMAB E TRASTUZUMAB (b ESTRADIOL (hypop (anovulation); FULI ESTROGENS, CON (neoplasm); ESTRIC DIPHOSPHATE (m (postmenopausal os carcinoma in situ); J	(acute myeloid leuke cer); TAK-901 (acute r hoid neoplasm); AM( 2 (neoplasm); PF-038 all cell lung carcinom MTITINB (non-small o EVATINIB (non-small ngiocarcinoma); BMS RTINIB (breast neoplas ( glioblastoma multif -26483327 (cancer) MTANSINE (neoplast ERUXTECAN (breast reast cancer); T-DM1 gonadism); ESTRADI VESTRANT (breast ca JUGATED (postmend) U (urinary tract infec soplasm); OSPEMIFE2 teoporosis); SYNTHE RAD1901 (Hot flashes RIFIED (breast cance	emia); BARASERTIB myeloid leukemia); Y -900 (cancer); CYC- 14735 (neoplasm) a); NERATINIB (nec ell lung carcinoma); l cell lung carcinoma; e00514 (non-small c asm); HEMAY-022 (t örme); MUBRITINIB m); TRASTUZUMAI t cancer); MARGETI (breast cancer) OL VALERATE (infi rrcinoma); ETHINYL ypausal osteoporosis) tion); POLYESTRAE VE (sexual dysfuncti IC CONJUGATED s); FISPEMIFENE (hy	(acute myeloid leui NS-314 (neoplasm); TII plasm); VANDETA TUCATINIB (HER2 ); POZIOTINIB (HER2 ); POZIOTINIB (nori (ll lung carcinoma); reast ancer); CUD (breast neoplasm); 3 (breast carcinoma) JXIMAB (breast car ertility); BAZEDOX ESTRADIOL (infer TAMOXIFEN (bre IOL PHOSPHATE m); LASOFOXIFEN (bre ESTROGENS, B (mp pogonadism); BRIL	cemia); CHIAURAN; KW-2449 (acute myt 2-607 (lymphoma); G NIB (thyroid cancer); Positive Breast Carci n-small cell lung carc SAPITINIB (breast ca C-101 (head and neck AC-480 (cancer); TAI ;; PERTUZUMAB (r cer); ERTUMAXOM. IFENE (obesity); CLC tillity); TOREMIFENE ast cancer); DIETHYI (neoplasen); DIETHYI (neoplasen); AFIMOXI ANESTRANT (breas	IB (ovarian cancer); eloid leukemia); SK-1070916 LAPATINIB noma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB inoma); PZ24714 : malignant <-285 (cancer); MP- ecoplasm); AB (breast cancer); MIPHENE (breast cancer); STILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL ZOXIFENE FENE (breast ductal t cancer);
AURKB ERBB2 (Small molecules) ERBB2 (Antibodies)	sarcoma); BI-S11283 ILORASERTIB (can- CENISERTIB (can- CENISERTIB (can- ceplasm); MK-655 AFATINIB (non-sm (neoplasm); DACO (breast cancer); TES VARLITINIB (cholai (metastasis); CANEI (metastasis); CANEI (metastasis); CANEI (metastasis); CANEI TRASTUZUMAB E TRASTUZUMAB E TRASTUZUMAB ( ESTRADIOL (hypo (anovulation); FUL) (STROGENS, CON (neoplasm); ESTRIC DIPHOSPHATE (ne (postmenopausal os carcinoma in situ); ESTROGENS, ESTE ACOLBIFENE (bree PROGESTEROME ( ULIPRISTAL ACET LEVONORGESTER MEDROXYPROGE fibroid); ETONOCE syndrome); NORGI fibroid); DANAZO	(acute myeloid leuke cer); TAK-901 (acute r hoid neoplasm); AM( 2 (neoplasm); PF-038 all cell lung carcinom MTITINB (non-small o EVATINIB (non-small ngiocarcinoma); BMS RTINIB (breast neoplas ( glioblastoma multif -26483327 (cancer) MTANSINE (neoplast ERUXTECAN (breast reast cancer); T-DM1 gonadism); ESTRADI VESTRANT (breast ca JUGATED (postmend) U (urinary tract infec soplasm); OSPEMIFE2 teoporosis); SYNTHE RAD1901 (Hot flashes RIFIED (breast cance	emia); BARASERTIB myeloid leukemia); 5 2-900 (cancer); CYC- 5-900 (cancer); CYC- 14735 (neoplasm) a); NERATINIB (nec ell lung carcinoma 400514 (non-small ca asm); HEMAY-022 (t forme); MUBRITINIB m); TRASTUZUMAI t cancer); MUBRITINIB m); TRASTUZUMAI t cancer); MUBRITINIB m); TRASTUZUMAI t cancer); MARGETI (breast cancer) OL VALERATE (inf rcrinoma); ETHINYL opausal osteoporosis) tion); POLYESTRAE NE (sexual dysfundi TIC CONJUGATED 5; FISPEMIFENE (hy r); SR16234 (breast ca CAL (uterine fibroid!); ; DROSPIRENONE (p DROXYPROGESTE E (hemorrhage); CYF ); MEGESTROL AC RETHINDRONE (p dema); ASOPRISNII	(acute myeloid leui NS-314 (neoplasm); Il6 (neoplasm); TI plasm); VANDETA TUCATINIB (HEIZ) ); POZIOTINIB (noi Il lung carcinoma); reast cancer); CUD (breast neoplasm); d (breast carcinoma) XIIMAB (breast can ertility); BAZEDOX ESTRADIOL (infer TADOXIFEN (brei OL PHOSPHATE m); LASOFOXIFEN (brei NOL PHOSPHATE m); LASOFOXIFEN (c NORETHINDRON Dysmenorrhea); Di QONE CAPROATE ROTERONE ACET ETATE (precocious septartum depressis (leiomyoma); NOR	xemia); CHIAURAN; KW-2449 (acute my 2-607 (lymphoma); G NIB (thyroid cancer); Positive Breast Carci n-small cell lung carc SAPITINIB (breast ca C-101 (head and neck AC-480 (cancer); TAI ; ; PERTUZUMAB (r carc); ERTUMAXOM; ; ; PERTUZUMAB (r carc); ERTUMAXOM; ; Coreconstruction); CLC lifty); TOREMIFENE (steoparosis); AR; (costeoparosis); AR; (co	IB (ovarian cancer); eloid leukemia); SK-1070916 LAPATINIB noma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB eloid anoma; STILBESTROL 20XIFENE FENE (breast ductal t cancer); STILBESTROL 20XIFENE FENE (breast ductal t cancer); State cancer); STILBESTROL 20XIFENE FENE (breast ductal t cancer); STILBESTROL 20XIFENE FENE (breast ductal t cancer); STILBESTROL 20XIFENE FENE (breast ductal t cancer); STILBESTROL 20XIFENE FENE (breast ductal t cancer); STREL (uterine ONE (persian gulf ACETATE (uterine trorrhagia);
AURKB ERBB2 (Small molecules) ERBB2 (Antibodies) ESR1	sarcoma); BI-S11283 ILORASERTIB (cam, CENISERTIB (imp (neoplasm); MK-655 AFATINIB (non-sm (neoplasm); DACO (breast cancer); TES VARLITINIB (cholai (metastasis); CANE 12 (neoplasm); JNJ TRASTUZUMAB E TRASTUZUMAB E TRASTUZUMAB (b ESTRADIOL (hypo) (anovulation); FUI ESTROGENS, CON (neoplasm); STRIC DIPHOSPHATE (nc (postmenopausa) os carcinoma in situ); I ESTROGENS, ESTRI COBIFENE (brea PROGESTERONE ( ULIPRISTAL ACET LEVONORGESTREL MEDROXYPROGE syndrome); NORGI fibroid); DANAZO NORGESTREL (enc (neoplasm) VOLASERTIB (acut	(acute myeloid leuke cer); TAK-901 (acute r hoid neoplasm); AM 22 (neoplasm); PF-038 all cell lung carcinom MITINIB (non-small o EVATINIB (non-small ngiocarcinoma); BMS- RTINIB (breast neopla 32 (glioblastoma multif 32 (glioblastoma multif 24648327 (cancer) MTANSINE (neoplasm DERUXTECAN (breast reast cancer); T-DMI gonadism); ESTRADI VESTRANT (breast ca 20 (urinary tract infect opolasm); OSPEMIFE1 RAD1901 (Hot flashes (RIFIED (breast cancer) 10 (urinary tract infect opolasm); OSPEMIFE1 RAD1901 (Hot flashes (RIFIED (breast cancer) 10 (Hot flashes (RIFIED (breast cancer) 10 (There in fibroid) 1 (Menorrhagia); HY STERC (HV infectior ESTIMATE (acne); NC L (diabetic macular e dometrial cancer); LO	emia); BARASERTIB myeloid leukemia); Y =>00 (cancer); CYC- 14735 (neoplasm) a); NERATINIB (nec ell lung carcinoma); l cell lung carcinoma); l cell nung carcinoma); l cell nung carcinoma); e osofit (non-small ci asm); HEMAY-022 (t forme); MUBRITINIB m); TRASTUZUMAI t cancer); MARGETI (breast cancer); MARGETI (breast cancer); OL VALERATE (infi rrcinoma); ETHINYL ypausal osteoporosis) tion); POLYESTRAE VE (sexual dysfuncti TIC CONJUGATED s); FISPEMIFENE (hy r); SR16234 (breast ci ZAL (uterine fibroid); ); DROSPIRENONE ( DROXYPROGESTE E (nemorthage); CYF dema); ASOPRISNIL NAPRISAN (breast ci BI-2536 (acute myel	(acute myeloid leui NS-314 (neoplasm); 116 (neoplasm); TTI plasm); VANDETA TUCATINIB (HER2 ); POZIOTINIB (nor il lung carcinoma); reast ancer); CUD (breast neoplasm); 3 (breast arcinoma) JXIMAB (breast carcinoma) JXIMAB (breast carcinoma) STRACEONS, B (mp pogonadism); BRIL Incer); ESTROCENS, B (mp pogonadism); BRIL Incer); ESTRORE (c NORETHINDRON Dysmenorrhea); D RONE CAPROATE ROTERONE ACE TATE (precocious patpartum depressio (leiomyoma); NOR ancer); PF-0501970; oid leukemia); ON	cemia); CHIAURAN; KW-2449 (acute my; 2-607 (lymphoma); G NIB (thyroid cancer); Positive Breast Carci n-small cell lung carc SAPITINIB (breast carc- c-101 (head and need AC-480 (cancer); TAI ;; PERTUZUMAB (r cer); ERTUMAXOM. IFENE (obesity); CLU (heoplasm); DIETHYI (neoplasm); DIETHYI (nother); DIETH	IB (ovarian cancer); eloid leukemia); SK-1070916 LAPATINIB noma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB inoma); PAB (breast cancer); MP- deoplasm); AB (breast cancer); MIPHENE (breast cancer); STILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL STILBESTROL CONE (persian gulf ACETATE (uterime trorrhagia); NAPRISTONE
AURKB ERBB2 (Small molecules) ERBB2 (Antibodies) ESR1 PGR	sarcoma); BI-S11283 ILORASERTIB (cam, CENISERTIB (ymp (neoplasm); MK-659 AFATINIB (non-sm (neoplasm); DACOI (breast cancer); TES VARLITINIB (cholar (metastasis); CANE at 2( neoplasm); JNJ TRASTUZUMAB E TRASTUZUMAB E TRASTUZUMAB ( GANCOTAMAB (the ESTRADIOL (hypoo (anovulation); FUL ESTROGENS, CON (neoplasm); ESTRUC (neoplasm); ESTRUC DIPHOSPHATE (net (postmenopausal os carcinoma in situ); I ESTROGENS, ESTE ACOLBIFENE (brea PROGESTERONE ( ULIPRISTAL ACET LEVONORGESTRE MEDROXYPROGE fibroid); ETONOGE syndrome); NORGESTREL (encor; MK-1496 (the DEFACTINIB (pand	(acute myeloid leuka cer); TAK-901 (acute r hoid neoplasm); AM 22 (neoplasm); PF-038 all cell lung carcinom MITINIB (non-small o EVATINIB (non-small ngiocarcinoma); BMS RTINIB (breast neopla 3 (glioblastoma multif 2-6483327 (cancer) MTANSINE (neoplass) SERUXTECAN (breast reast cancer); T-DMI gonadism); ESTRADI gonadism); ESTRADI VESTRANT (breast ca JUGATED (postment 2), Urinary tract infec teoporosis); SYNTHE RAD1901 (Hot flashes RIFIED (breast cancer) att cancer) infertility); ULIPRIST ATE (uterine fibroid) 1, (Monorrhagia); HY STERONE ACETATE SSTREL (HIV infectior SSTMATE (ance); NU	emia); BARASERTIB myeloid leukemia); Y c-900 (cancer); CYC- 14735 (neoplasm) a); NERATINIB (nec ell lung carcinoma); l cell ung carcinoma); d cell ung carcinoma); m); TRASTUZUMAI t cancer); MUBRITINIB m); TRASTUZUMAI t cancer); MUBRITINIB m); TRASTUZUMAI t cancer); MARGETI (breast cancer) OL VALERATE (inf (breast cancer); OL VALERATE (inf (breast cancer); OL VALERATE (inf (breast cancer); NE (sexual osteoporosis) tion); POLYESTRAL SE (sexual osteoporosis) tion); POLYESTRAL NE (sexual osteoporosis) tion); SR16234 (breast cancer); AL (uterine fibroid); ; DROSPIRENONE DROXYPROGESTE (hemorthage); CYF s); MEGESTROL AC ORETHINDRONE (p dema); ASORISINII, NAPRISAN (breast cancer); Hartinoma); GSK-2256(	(acute myeloid leui NS-314 (neoplasm); 116 (neoplasm); TTI plasm); VANDETA TUCATINIB (HEIZ) ); POZIOTINIB (nor ill lung carcinoma); reast ancer); CUD (breast neoplasm); 3 (breast carcinoma) XIMAB (breast car ertility); BAZEDOX ESTRADIOL (information); 100 PHOSPHATE m); LASOFOXIFEN (breast Carcinoma); NORETHINDRON Dysmenorrhea); D' RONE CAPROATE ROTERONE ACET ETATE (precoious sistpartum depressis (leiomyoma); NOR ancer); PF-0501970; oid leukemia); ONY	kemia); CHIAURAN; KW-2449 (acute myt 2-607 (lymphoma); G NIB (thyroid cancer); Positive Breast Carci n-small cell lung carc SAPITINIB (breast carc- c-101 (head and need AC-480 (cancer); TAI ; PERTUZUMAB (n cer); ERTUMAXOM, FFENE (obesity); CLC hilty); TOREMIFENE ast cancer); DIETHYI (neoplasm); DIETHYI (neoplasm); DIETHYI (akosporosis); AR; enopause); AFIMOXI ANESTRANT (breas besity); GTX-758 (pn E ACETATE (hypog yDROGESTERONE ( (premature birth); ATE (ance); DESOGE puberty); MIFEPRISTIONE ELGESTROMIN (Me i (uterine fibroid); OI 'ANSERTIB (prostate RTIB (acute myeloid	IB (ovarian cancer); eloid leukemia); SK-1070916 LAPATINIB noma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB inoma); PYROTINIB inoma); andignant <<285 (cancer); MP- ueoplasm); AB (breast cancer); MIPHENE (breast cancer); MIPHENE (breast cancer); STILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL LSTILBESTROL STI

**Figure Supplementary 4**. Available drugs against validated proteins divided in small molecules and antibodies. A description of current clinical applications with the commercial names is given below. Source: Open Target Platform [4].

## References

 Coll-de la Rubia, E.; Martinez-Garcia, E.; Dittmar, G.; Gil-Moreno, A.; Cabrera, S.; Colas, E. Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis. J. Clin. Med. 2020, 9, 1900, doi:10.3390/jcm9061900.

- 21 22
- 23
- 24

- Consortium, T.U.; Bateman, A.; Martin, M.-J.; Orchard, S.; Magrane, M.; Agivetova, R.; Ahmad, S.; Alpi, E.; Bowler-Barnett, 27 E.H.; Britto, R.; et al. UniProt: The universal protein knowledgebase in 2021. *Nucleic Acids Res.* 2021, 49, D480–D489, 28 doi:10.1093/NAR/GKAA1100.
- Vasaikar, S.V.; Deshmukh, A.P.; den Hollander, P.; Addanki, S.; Kuburich, N.A.; Kudaravalli, S.; Joseph, R.; Chang, J.T.;
   Soundararajan, R.; Mani, S.A. EMTome: A resource for pan-cancer analysis of epithelial-mesenchymal transition genes and signatures. *Br. J. Cancer* 2020, *124*, 259–269, doi:10.1038/s41416-020-01178-9.
- Ochoa, D.; Hercules, A.; Carmona, M.; Suveges, D.; Gonzalez-Uriarte, A.; Malangone, C.; Miranda, A.; Fumis, L.; Carvalho-Silva, D.; Spitzer, M.; et al. Open Targets Platform: Supporting systematic drug-target identification and prioritisation. *Nucleic Acids Res.* 2021, 49, D1302–D1310, doi:10.1093/nar/gkaa1027.

36